替吉奥治疗结肠癌的研究  

Tegafur Capsules for Colon Cancer Research Progress

作　　者：吴元玉[1] 范恩学[1] 宋佳 王率 贾国梁[1] 

机构地区：[1]吉林大学第二医院,吉林长春130000 [2]乳山市人民医院,山东威海264200

出　　处：《现代生物医学进展》2014年第1期102-103,67,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨替吉奥治疗结肠癌的疗效。方法:75例经病理组织学确诊的结肠癌患者,分为A、B、C组。A组:替吉奥联合奥沙利铂(艾恒)25例。B组:5-Fu/LV联合奥沙利铂(艾恒)25例。C组:替吉奥单药治疗25例。观察疗效、疾病控制率及不良反应。结果:A组、C组与B组对比,不良反应发生率明显降低。A组有效率48%,疾病控制率88%。B组有效率28%,疾病控制率84%。C组有效率32%,疾病控制率80%。结论:替吉奥是结肠癌辅助化疗联合用药及单药治疗老年结直肠癌较好的治疗药物。Objective： To investigate the efficacy of tegafur capsules for colon cancer. Methods： Seventy-five cases of colon cancer confirmed by pathology were included. The patients in group A （ n = 25） received tegafur capsules plus oxaliplatin, while those in group B （ n =25） were treated with 5-Fu/LV plus oxaliplatin. The patients in group C （ n = 25） received tegafur capsules monotherapy for colon cancer. Results： The side effects decreased significantly in group A and C than that in B. The effective rates was 48%, 28% and 32% in group A, B and C. And the disease control rate was 88%, 84% and 80% in group A, B and C. Conclusion： Tegafur capsules is better for colon cancer in new adjuvant chemotherapy or Adjuvant Chemotherapy after Radical Surgery. Tegafur capsules monotherapy treatment older colon cancer curative effect is accurate.

关 键 词：替吉奥 奥沙利铂 5氟尿嘧啶 结肠癌 

分 类 号：R735.35[医药卫生—肿瘤]